Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors

Ichnos Glenmark Innovation (IGI) announced ISB 2301, a first-in-class multispecific antibody that targets three tumor-associated antigens and activates both T cells and NK cells for solid tumor treatment. The candidate, developed using IGI's proprietary BEAT® platform, demonstrated favorable safety profiles in preclinical studies and is expected to advance toward clinical trials with an IND submission planned by end of 2026.